September Launch Eyed For Cephalon/J&J’s Sparlon

Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet